Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently all patients that have freeze-all ICSI treatment cycles have the start of their FET cycle scheduled with the use of OCP. While an excellent pregnancy rate (75%) for the patients that have a blastocyst transfer has been maintained over time, 15% of started FET cycles are being cancelled because of premature luteinization, and the treatment (to transfer) takes approximately 89 days. The use of a Lucrin depot may reduce the number of cycles cancelled and reduce the treatment time to approximately 69 days. The use of no drugs and allowing the normal menstrual cycle to determine the time to start the FET cycle may suit some patients. Whether these benefits can be obtained while still maintaining the current FET pregnancy rate will be the main focus of the trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blastocyst Culture Using Time-lapse in Good Prognosis IVF Patients and Elective Single Embryo Transfer

NCT01773603

Infertility

TERMINATED NA

Idealizing Pregnancy Outcome With Single Blastocyst Transfer in a FET Cycle

NCT01987856

Pregnancy

WITHDRAWN NA

Immediate Versus Postponed Single Blastocyst Transfer in Programmed or Stimulated Cycle Frozen Embryo Transfer

NCT06304792

Infertility IVF

RECRUITING NA

Protocols for Improved in Vitro Fertilization (IVF) Outcomes

NCT00334243

Infertility

TERMINATED PHASE4

Comparing the Ongoing Pregnancy Rate for Vitrification of Day-4 Morula With Day-5 Blast

NCT03787901

Infertility

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The patients will undergo standard assisted conception procedures; controlled ovarian stimulation (COS), oocyte pickup procedure (OPU), ICSI, embryo culture, blastocyst vitrification and frozen embryo transfer. If sufficient (\>2) viable blastocyst develop from the in vitro culture of their embryos, all viable blastocysts will be cryopreserved using a routine vitrification procedure. This is the eligible patient population. On the day the last blastocyst(s) are frozen the patients will be given a further opportunity to ask questions and if satisfied they will be asked to complete a trial consent. At this point patients will be randomized by numeric code and given a schedule and drug prescription for scheduling the start of their hormone supplemented frozen embryo transfer cycle. During the scheduling period the patients will follow the drug prescription provided . After the completion of their treatment - the transfer of one or two vitrified-warmed blastocyst - the patients from both groups will receive identical luteal support drug schedules and prescriptions. A blood test will be performed on the 15th day of progesterone supplementation, to determine the βhCG blood concentration. Currently at Antalya IVF, approximately 75% of patients who have blastocysts transferred in a frozen embryo transfer cycle have a positive biochemical pregnancy test, \>29 international units per litre (IU/L) of human chorionic gonadotropin (βhCG). If pregnant, patients will continue using estrogen and progesterone supplementation for a further 8 weeks. At 7 weeks of gestation (5 weeks after embryo transfer ) the patients will receive a transvaginal ultrasound scan (TVUS) to check for pregnancy viability (fetal sac with cardiac activity). Thereafter the patients will have regular TVUS to follow fetal development. At 20 weeks of gestation a TVUS will be performed to confirm an ongoing pregnancy (normal fetal development).

All drug packs are delivered to the clinic by the pharmacy after receiving the prescription. A staff member will verify the code on the prescription with randomization code allocated to the patient. The pack will then be given to the patient after verbally confirming patient identity. The packs will also contain a drug use instruction sheet and a trial information sheet.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lucrin depot, artificial cycle start

intramuscular administration of Lucrin depot (half dose of 3.75mg) on the 5th day following oocyte retrieval

Group Type EXPERIMENTAL

Lucrin depot

Intervention Type DRUG

scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle

OCP active, artificial cycle start

to take active OCP tablets (1 per day) from the 10th day following oocyte retrieval for at least 21 days

Group Type ACTIVE_COMPARATOR

OCP

Intervention Type DRUG

to schedule the start of the artificial cycle

Natural, menstrual period

to wait for the second bleed to commence the artificial FET cycle

Group Type EXPERIMENTAL

Natural

Intervention Type OTHER

to use the normal menstrual period to schedule treatment start

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lucrin depot

scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle

Intervention Type DRUG

OCP

to schedule the start of the artificial cycle

Intervention Type DRUG

Natural

to use the normal menstrual period to schedule treatment start

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* If patients have \>2 blastocysts vitrified

Exclusion Criteria

* All patients not willing to participate in the study
* Patients with any known adverse reaction to one or the other of the drugs prescribed
* All patients that have no surviving blastocysts for transfer

Minimum Eligible Age

20 Years

Maximum Eligible Age

42 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes